Lotiglipron

| Cat. No.: | HY-153865 | | |
|--------------------|--|----------------|----------|
| CAS No.: | 2401892-75 | -7 | |
| Molecular Formula: | C ₃₁ H ₃₁ ClN ₄ C |) ₅ | |
| Molecular Weight: | 575.05 | | |
| Target: | GCGR | | |
| Pathway: | GPCR/G Pro | otein | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |
| | | | |

SOLVENT & SOLUBILITY

| | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|--|------------------------------|-------------------------------|-----------|-----------|------------|
| | | 1 mM | 1.7390 mL | 8.6949 mL | 17.3898 mL |
| | | 5 mM | 0.3478 mL | 1.7390 mL | 3.4780 mL |
| | | 10 mM | 0.1739 mL | 0.8695 mL | 1.7390 mL |

BIOLOGICAL ACTIVITY Description Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM)^[1].

REFERENCES

[1]. Buckeridge C, et al. Once-daily oral small molecule GLP-1R agonist PF-07081532 reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity. Hybrid 58th EASD Annual Meeting; Sept 19–23, 2022 (abstr 114).

Caution: Product has not been fully validated for medical applications. For research use only.


Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA





Product Data Sheet